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Abstract
Background: Gleevec (aka STI571, Imatinib) is a recently FDA approved anti-tumor drug for
chronic myelogenous leukemia. Gleevec binds specifically to BCR-ABL tyrosine kinase and inhibit
the tyrosine kinase activity. It cross-reacts with another two important membrane tyrosine kinase
receptors, c-kit and PDGF receptors. We sought to investigate if Gleevec has a potential role in
treatment of non-small cell lung cancer.
Results: We have shown that Gleevec alone can inhibit the A549 lung cancer cell growth in dose-
dependent manner, and the optimal concentration of Gleevec inhibition of A549 cell growth is at
the range of 2–3 µM (IC50). We have also shown that A549 cells are resistant to cisplatin
treatment (IC50 64 µM). Addition of Gleevec to the A549 cells treated with cisplatin resulted in a
synergistic cell killing effect, suggesting that Gleevec can potentiate the effect of cisplatin on A549
cells. We also showed that the A549 lung cancer cells expresses the platelet derived growth factor
receptor α, and the inhibitory effects of Gleevec on A549 cells is likely mediated through inhibition
of PDGFR α phosphorylation. We further tested 33 lung cancer patients' tumor specimens to see
the frequency of PDGFR-α expression by tissue micro-arrays and immunohistochemistry. We
found that 16 of the 18 squamous carcinomas (89%), 11 of the 11 adenocarcinomas (100%), and 4
of the 4 small cell lung cancers (100%) expressed PDGFR-α.
Conclusion: These results suggest a potential role of Gleevec as adjuvant therapeutic agent for
treatment of non-small cell lung cancer.
Background
Lung cancer is the leading killer of all cancer patients. It is
generally classified as small cell carcinoma and non-small
cell carcinoma. Treatment of lung cancer is less than opti-
mal and the mean survival for advanced lung cancer pa-
tient is less than one year regardless what treatment
regimen was used [1]. A new approach other than conven-
tional chemoradiation therapy is needed for prolonged
survival of lung cancer. Emerging new treatment modali-
ties are generally targeted to specific tyrosine kinases of
the tumor cells through basically two independent ap-
proaches [2]. One is to use highly specific monoclonal an-
tibody to target the membrane receptors of growth factors
important for tumor cell growth, and the antibody/anti-
gen complex evokes host immune system to kill the tumor
cells. This approach is exemplified by Her2/neu receptor
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in breast cancer patients and Herceptin [3]. The second
approach is to develop small organic molecules targeting
the specific tyrosine kinases in the signaling pathway in
the tumor cells that can easily gain access into the tumor
cells. This approach is best exemplified by Gleevec and
BCR-ABL fusion kinase in chronic myelogenous leukemia
[4].
Gleevec (also known as STI571, Imatinib from Novartis
Pharmaceutical Inc.), a recently FDA approved drug for
chronic myelogenous leukemia, is an ATP analogue, and
it competitively binds to and inhibits BCR-ABL tyrosine
kinase, resulted from the chromosomal translocation t(9;
22). Gleevec has been shown to induce clinical, hemato-
logical and molecular remissions for CML patients [4]. It
cross-reacts with two other important growth factor recep-
tors containing tyrosine kinase domains, c-kit and PDGF
receptors, that play important roles in growth and prolif-
eration of a variety of cell types [5]. C-kit (also known as
CD117) is frequently mutated in gastrointestinal stromal
tumor (GIST), and the mutated c-kit shows higher tyro-
sine kinase activity. Gleevec has been demonstrated to in-
hibit the growth and proliferation of GIST, and induce
complete or partial clinical remission in GIST patients
[6,7]. Recently Gleevec was showed to inhibit the growth
of dermatofibrosarcma protuberans (DFSP) through in-
hibiting the PDGF receptor [8,9].
As a part of effort to evaluate the newly emerging drugs for
lung cancer, we studied the role of Gleevec on non-small
cell lung cancer. We previously showed that non-small
cell lung cancers express minimal (negligible) level of c-
kit (Zhang, P., unpublished). Therefore it is unlikely that
Gleevec exerts the effect, if any, through c-kit on non-
small cell lung cancer. We reported here a study of inhib-
itory effect of Gleevec on lung cancer cells (A549 cells) in
vitro. We showed that Gleevec alone can inhibit the
growth and proliferation of A549 cells at the known ther-
apeutic concentration for CML. Addition of Gleevec to
A549 cells with cisplatin induced cell death synergistical-
ly, suggesting Gleevec can potentiate the cisplatin effect
on A549 cells. We have demonstrated that A549 cells ex-
press PDGFR α, one of the known potential targets for
Gleevec effect. The inhibitory effect of Gleevec on the
A549 cells is likely mediated through inhibition of PDGF
receptor α phosphorylation. We further tested 33 lung
cancer patients' tumor specimens, and showed that most
of the lung cancer tumor specimens expressed PDGFR-α.
These results provided important in vitro data to support
the notion that Gleevec can inhibit the A549 cell growth
and proliferation, and may potentially offer a treatment
option for lung cancer either alone or in conjunction with
chemotherapy drug cisplatin.
Results
Gleevec inhibited the A549 cell growth in a dose-depend-
ent manner
We first test to see if Gleevec can inhibit the growth of
A549 cells under the culture conditions. We have chosen
to perform the experiments under the normal culture con-
dition since we reasoned that the effect of Gleevec on tu-
mor cells, if any, should be under the normal, not serum
free condition. Therefore, we chose to add the drug direct-
ly into the culture medium containing 5% fetal calf se-
rum. A549 lung cancer cells were plated at two cell
densities into the 96 well plates, and Gleevec was added
to the culture medium. We used the MTT assays to assess
the viability of the tumor cells treated with or without the
drug. It was evident that increasing concentrations of
Gleevec in the culture medium inhibited the growth of
A549 cells in a dose dependent manner. The concentra-
tion of Gleevec to inhibit 50% cell growth (IC50) was es-
timated to be around 2–3 µM (Figure 1), whereas the
IC50 of cisplatin on A549 cells was estimated to be 64–70
µM (Figure 2). We have also seen that Gleevec can inhibit
the growth of human 293 kidney cells, but at slightly
higher concentration (4 µM). The IC50 concentration for
A549 cells didn't appear to have inhibitory effects on hu-
man 293 cells (Figure 3). These results showed that
Gleevec alone can indeed inhibit the growth of A549 lung
carcinoma cells. The inhibitory effect of Gleevec on the
A549 cells appeared to be in a therapeutic range of the
drug as demonstrated in chronic myelogenous leukemia
cells from the patients.
Gleevec potentiated the cell-killing effect of cisplatin
One of the major reasons of testing Gleevec for treatment
of non-small cell lung carcinoma is to see if the specific ty-
rosine kinase inhibitor Gleevec, and other potential small
molecules currently on clinical trials, can be used as an ad-
juvant therapeutic agent in combination with convention-
al chemotherapy. We sought to see if Gleevec can
potentiate the cell killing effects of cisplatin, the leading
chemotherapeutic drug for almost all advanced cancer pa-
tients. We used the IC50 concentrations for both Gleevec
and cisplatin to treat A549 cells in culture, and assessed
the viability of the cells by MTT assays at the different time
points (Figure 4). Gleevec (2 µM) and cisplatin (64 µM)
both inhibited the growth of the tumor cells individually
after treatment of the cells for 48 hour. Combination of
Gleevec and cisplatin synergistically inhibited the growth
of A549 cells (Figure 4). This synergistic effect of Gleevec
and cisplatin on A549 lung cancer cells were not seen for
human 293 kidney cells (Figure 5).
Expression of PDGFR-α in the A549 lung cancer cells
Since the effect of Gleevec is mediated through inhibiting
BCR-ABL tyrosine kinase, c-kit, and PDGF receptors, we
are interested in the potential target for Gleevec effect inMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/1
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Figure 1
Inhibitory effects of Gleevec on A549 lung cancer cells in a 
dose-dependent manner using two different cell densities in 
the serum-containing medium. Gleevec concentrations were 
as listed ranging from 0.5 to 8 µM. Unless stated otherwise, 
the cell culture was maintained and treated with the drugs 
for 48 hours before being analyzed by MTT assays. The 
results were the mean of five different readings (± 2SD) 
within in one experiment, and the figures were representa-
tive of three independent experiments.
Figure 2
Dose-dependent inhibition of A549 cell growth by cisplatin 
using two different cell densities. Cisplatin concentrations 
were used as listed ranging from 16 to 96 µM.
19
Figure 3
Comparison of Gleevec effects on A540 cells with the human 
293 kidney cells. A549 cells and human 293 cells were cul-
tured and treated with Gleevec as described above using the 
concentrations listed. The culture conditions were identical 
to those described in Figure 1.
Figure 4
The effects of either Gleevec or cisplatin alone or in combi-
nation on A549 lung cancer cells. The tumor cells were 
treated with either drug alone or in combination for various 
times using IC50 concentrations for both Gleevec (2 µM) 
and cisplatin (64 µM). The synergistic effect was seen at 48 
hours after treatment. Control cells were treated with nei-
ther drug.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/1
Page 4 of 9
(page number not for citation purposes)
the lung cancer cells. We have previously showed by im-
munohistochemical staining that in 54 primary non-
small cell lung carcinoma specimens, expression of c-kit
was weak and minimal, if any (Tang and Zhang, unpub-
lished observation). We sought to determine the expres-
sion levels of PDGF receptors α and β in A549 cells and
the primary non-small cell lung carcinoma by immun-
ofluorescent and immunohistochemical staining meth-
ods. In A549 cells, expression of PDGFR-α, not PDGFR-β,
was detected with strong cytoplasmic and membrane
staining patterns (Figure 6 and 7). There was no demon-
strable nuclear staining signal. We further detected the
presence of PDGFR-α in the whole cell lysates of A549
cells by Western blotting analysis (Figure 8). A549 cells
were cultured under the condition described, and the cells
were lysed and the whole cell proteins were separated on
7.5% SDS-PAGE. The proteins were transferred onto ni-
trocellulose membrane, and the PDGFR-α was detected
with anti-PDGFR-α antibody (Santa Cruz Biotechnologies
Inc.). Treatment of the cells with Gleevec at two concen-
trations did not influence the expression of PDGFR-α ex-
pression in the cells. PDGFR-β was not detected in A549
cells using both immunofluorescent staining and Western
blot analyses (Data not shown).
Microarrays and immunohistochemical staining
Existing data suggest that Gleevec can exert its inhibitory
effect on tumor cells through inhibiting PDGF receptor
function, and we have shown that the primary non-small
cells lung cancer expressed minimal c-Kit. We would like
to see if PDGF receptor expression in lung cancer patients
is frequent finding, and this could potentially provide a
cellular mechanism by which Gleevec inhibits the lung
cancer tumor growth. We used the tumor tissue micro-ar-
ray technique using the high-density lung tissue arrays
from Clinomic Biosciences Inc, MA. Lung tissue micro-ar-
ray slides containing 33 primary lung cancer tumor speci-
mens with the corresponding normal lung tissues were
used for immunohistochemical staining using anti-PDG-
FR-α and β antibodies as described. The clinical diagnoses
of lung cancers were reviewed and confirmed. Using clin-
ical diagnostic criteria, the immunostaining patterns and
intensities were verified by two independent board certi-
fied surgical pathologists. Since immunohistochemical
staining is a semi-quantitative method, we scored the
staining intensities arbitrarily as 1+, 2+ and 3+ (Figure 9).
There were 18 cases of squamous carcinomas of the lung
within the tissue array slide, and 16 of the 18 cases were
positive for PDGFR-α (89%). 7 of the 16 cases were scored
1+ (39%), 5 cases 2+ (28%) and 4 cases 3+ positivity
(22%) (Table 1). There were 11 of the 11 adenocarcinoma
specimens that were positive for PDGFR-α (100%) [6 cas-
es 1+ (55%), 3 cases 2+ (27%), 2 cases 3+ (18%) respec-
tively]. Small cell carcinomas were also positive
expression of PDGFR-α [4 cases 2+ (100%)]. Two cases of
malignant mesotheliomas were negative for PDGFR-α.
The corresponding normal lung tissues were found to be
negative for PDGFR-α. Although there were some intersti-
tial staining signals for PDGFR-β, the tumor tissues were
negative for PDGFR-β (Figure 7, micro-array data not
shown). These results demonstrated that PDGFR-α ex-
pression is elevated in the tumor tissues compared to nor-
mal lung parenchyma, and the expression of PDGFR-α in
tumor tissue may play important roles in tumor growth
and progression.
Discussion
Gleevec is the first tyrosine kinase inhibitor that has been
proven to be effective for clinical cancer patients, and its
design is based purely on the inhibitory effect of the com-
pound on the intracellular BCR-ABL tyrosine kinase. This
represents a new direction in drug design targeting specific
tyrosine kinases important for intracellular signal trans-
duction pathways. There are many other small organic
molecules targeting different tyrosine kinases in horizon.
From the clinical standpoint, it will be of great importance
to see this line of new molecules to synergize with conven-
tional chemotherapy or sensitize the tumor cells to con-
ventional chemoradiation therapy. Our current study
showed that the small organic molecules such as Gleevec
targeting the specific tyrosine kinases can not only inhibit
the tumor cell growth alone, but also synergize with cispl-
atin in induction of tumor cell death.
Figure 5
The effects of either Gleevec or cisplatin alone or in combi-
nation on human 293 kidney cells. The drug concentrations 
were as described for Figure 4. Control cells were treated 
with neither drug.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/1
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Gleevec effects vs drug toxicity
We have shown in this study that Gleevec alone can inhib-
it the growth of A549 cells at the concentration of 2–3 µM
(IC50). This is within the known therapeutic ranges for
patients with CML, since the plasma levels of Gleevec in-
ducing hematologic and cytogenetic response in patients
with CML were reported to be in the range of 0.1–3.4 µg/
ml (0.17–5.68 µM) after treatment with 25–600 mg /day
[4]. In our system, the level of Gleevec at the tested con-
centration was in the low micromolar ranges, and the in-
hibitory effect of Gleevec on A549 cells is likely to be
genuine through binding to the receptor, not due to the
toxic effects of the drug. This inhibitory effect can also be
seen with the human kidney 293 cells with slight higher
IC50. At the concentration of 4 µM or higher, the inhibi-
tory effect of Gleevec on both A549 and 293 cells were
found to be identical (Figure 2 and 3). Higher concentra-
tion than 6 µM in the cell culture condition is unlikely to
be translated to clinical patients, since the adverse effects
of the drug will become intolerable for the patients.
Potential target of Gleevec in lung cancers
Gleevec was designed to inhibit the BCR-ABL tyrosine ki-
nase, and it cross-reacts with c-kit and PDGFR [5]. In non-
small cell lung cancer, BCR-ABL expression has never been
reported, and it is unlikely that BCR-ABL fusion protein
plays any role in lung cancer. There has been no report to
link cellular ABL kinase mutation to any cancer patients
except BCR-ABL in CML, although the detailed c-Abl func-
tion has not been extensively studied in lung cancer pa-
tients. CAbl is a tyrosine kinase that plays important roles
in cell growth, differentiation and apoptosis. Although c-
Abl mutations have not been reported in human cancers,
c-Abl related protein, ARG (or Abl-2), was shown to be
regulated in non-small cell lung cancers by hypermethyl-
ation (Dr. Steven Reynolds, National Institute of Occupa-
tional and Safety Health, Morgantown, WV, personal
communication). ARG shares significant homology with
c-Abl throughout the amino acid sequences. Gleevec has
been shown to inhibit ARG tyrosine kinase [10](Dr. Jean
Wang, Biology, University of California San Diego, per-
sonal communication), although the functional signifi-
cance of ARG kinase in lung cancer is yet to be elucidated.
We have studied the expression of c-kit (CD117) in the
non-small cell lung cancer patients, and we found that ap-
proximately 13% of the tumor specimens were weakly
positive for c-kit. The level of expression is generally weak
(1+). These results lead us to find an alternative target for
Gleevec, because of the low expression level and low fre-
quency of expression of c-kit in the lung cancer patients.
PDGFR expression in lung cancer
We have shown convincingly that lung cancer cell A549
expressed PDGFR-α both by immunostaining the cells
and by Western blot analysis. PDGF receptors are widely
Figure 6
Immunofluorescent stainings of A549 cells using anti-PDGFR-α and β antibodies. The secondary antibody was conjugated with 
Texas red fluorescent dye. The photographs were taken at the magnifications of 400X and 1000X.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/1
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Figure 7
Immunohistochemical staining of human non-small cell lung cancer tumor specimen with anti-PDGFR-α antibody. The photo-
graphs were taken at the magnifications of 400X.
Figure 8
Western blot analyses of PDGFR-α in the whole A549 cell lysates. The whole cell lysates were separated on 7.5% SDS-PAGE 
and analyzed by Western blot using anti-PDGFR-α antibody. Treatment of A549 cells with Gleevec showed no effect on the 
PDGFR-α protein expression.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/1
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expressed in a variety of tissues, and the levels of expres-
sion in normal tissues are minimal. Over-expression of
PDGFR has been reported in a variety of human tumors
including glioma and glioblastoma, pancreatic and colon-
ic cancers, breast, bone and ovarian tumors [11]. In nor-
mal cells, expression of PDGFR can be seen in the
fibroblasts and the smooth muscle cells in the lung and
airway [12]. There is so far to our knowledge no report to
link the expression of PDGFR to lung cancer. Since it has
been reported that Gleevec can inhibit the function of
PDGFR under the cell culture conditions, it is likely that
Gleevec exerts its inhibitory effects on A549 lung cancer
cells through inhibiting the PDGFR function.
Synergistic effect of Gleevec and cisplatin on A549 cells
We have shown that Gleevec can exert its effect synergisti-
cally with cisplatin. Cisplatin causes two types of DNA
damage, DNA adducts and inter-stranded cross-linking,
resulting in activation of apoptosis pathway in the target
tumor cells [13,14]. Our results suggest that inhibition of
tyrosine kinase activity of the potential targets by Gleevec
appear to potentiate the effect of cisplatin in DNA-damage
induced apoptosis in A549 cells. Although the underlying
mechanism of such synergism is unclear, it is of great in-
terest to combine the two drugs in clinical lung cancer pa-
tients to see if the synergy of the two drugs exists under the
physiological conditions. It has been widely thought, but
never been proven that the specific tyrosine kinase inhib-
itors such as Gleevec can be used as adjuvant therapy in
combination with conventional chemotherapy, because
the limited clinical trial data suggests only a marginal ben-
efits using this kind of drug to treat the cancer alone (John
Rogers, WVU Cancer center, ECOG trial member, person-
al communication). Current study results suggests that
Figure 9
Immunohistochemical staining of lung cancer tumor specimens using the tissue micro-arrays and the anti-PDGFR-α antibody. 
The staining intensities were scored 1+, 2+ and 3+ for all the tumors. The staining patterns were cytoplasmic and membrane. 
The magnification was at 400X for all the sections.
Table 1: Summary of PDFGR-α expression in lung cancer specimens
Cancer type Total Negative Positive % positive
1+ 2+ 3+
Squamous carcinoma 18 2 7 (39%) 5 (28%) 4 (22%) 89%
Adenocarcinoma 11 0 6 (55%) 3 (27%) 2 (18%) 100%
Small cell carcinoma 4 0 0 4 (100%) 0 100%
Mesothelioma 2 2 0%Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/1
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Gleevec can potentiate the cisplatin effect on A549 lung
cancer cells, and these findings provide important in vitro
data for further testing the possibility of using Gleevec as
adjuvant therapy for clinical lung cancer patients.
Methods
Cell culture and drug testing
Lung cancer cell line A549 cells were cultured in DMEM
with 5% fetal calf serum as described. The cells are seeded
in 96-well plate at the cell density of 2–4 × 104 per well as
indicated, and the tumor cells were cultured in the medi-
um containing serum. Cisplatin was purchased from Sig-
ma Chemicals (St. Louis, MO), and dissolved in water at
the concentration of 32 mM. The Gleevec (Novartis Phar-
maceuticals. Inc., NJ) was purchased from the outpatient
pharmacy at West Virginia University and dissolved in wa-
ter at the concentration of 1 mM. The experimental proce-
dure for the cisplatin and Gleevec treatment was the
following: The A549 cells and human 293 cells were plat-
ed into the 96 well plates at the cell density indicated and
the cells were allowed to attach overnight. The attached
cells in the plates were washed once with PBS and re-
placed with fresh medium containing various concentra-
tions of drugs indicated. The MTT assays were performed
after 48 hours of continuous incubation with medium
containing the drugs. The values shown in the figures are
mean readings from five wells in each experiments and
representative of three independent experiments.
MTT assays
We have performed a series of MTT assays to determine
the effects of the anti-tumor drug STI571 on the number
of A540 lung cancer cells and human 293 kidney cells.
The assay is based upon the cleavage of the yellow tetrazo-
lium salt MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide] to purple formazan crystals by met-
abolically active cells [15]. The tested concentration of
Gleevec ranged from 0.5 to 8 µM. The tumor cells were
seeded into 96-well culture plate, and maintained for cul-
ture for 24 hours before the first compound was added to
the medium. The cultured cells were incubated in a medi-
um containing 5% serum and treated with Gleevec for 48
hours. After treatment, 10 µl of MTT labeling reagent were
added to each well and plates were incubated at 37°C for
4 h. Following MTT incubation, the cultures were solu-
blized and the spectrophotometric absorbance of the sam-
ples was detected by using a microtiter plate reader. The
wavelength to measure absorbance of formazan product
is 570 nm, with a reference wavelength of 750 nm.
Immunofluorescent staining of the cultured cells
The A549 cells were cultured as described on the cover-
slips, and fixed with 3.7% paraformaldehyde for 10 min-
utes at room temperature. The fixed cells were
permeablized with 3% Triton X-100 in PBS and directly
used for immunofluorescent and immunocytochemical
stainings. The primary anti-PDGFR-α antibody was pur-
chased from Santa Cruz Biotechnologies Inc (Santa Cruz,
CA). The secondary antibody for immunofluorescent la-
beling was from Molecular Probe Inc. (Portland, OR).
Lung tumor tissue microarrays and immunohistochemical 
staining
The high-density lung cancer tissue microarray slides were
made in Clinomics Bisciences Inc. MA, and was used for
immunohistochemical staining for PDGFR-a. Briefly, the
tissue microarray slides were sectioned at 5 micron in
thickness and heated to 65°C for 10 minutes to de-parafi-
nize the tissues. The slides were washed three times in xy-
lene, then dehydrated and rehydrated in 100%, 95% and
70% ethanol. The tissue sections were finally washed with
PBS once before going through the antigen retrieval proc-
ess. The antigen retrieval was performed using citrate buff-
er (pH 7.4) at 90°C for 30 minutes. The
immunohistochemical staining was performed using Ven-
tana Bench Mark II automated staining device following
the manufacturer's instruction (Ventana Medical Inc. Tuc-
son, AZ). The primary PDGFR-α antibody was from Santa
Cruz Biotechnologies Inc (Santa Cruz, CA). The tumor
section slides and the immunostaining patterns were re-
viewed by two independent practicing surgical patholo-
gists, and the signal intensities were scored at 1+, 2+ and
3+. The staining characteristics of all tumors were summa-
rized in Table 1.
Western blotting
The A549 cells were maintained in the culture condition
as described above. Western blotting analyses of PDGF re-
ceptors were performed using a previously described
method [16]. Briefly, the tumor cells were treated with
Gleevec at the various concentrations for 6 hours. The
whole cell extracts were prepared and used for Western
blot with anti-PDGF receptor α using RIPA buffer contain-
ing SDS. The whole cell extracts were separated on the
7.5% SDS PAGE and transferred onto nitrocellulose mem-
brane by electroblotting. The primary antibody was incu-
bated in the 5% non-fat milk with the proteins on the
membrane overnight at 4°C, and the protein of interest
was visualized by the enhanced chemiluminescent meth-
od (ECL). The anti-PDGF receptor α antibody was used at
1:500 (Santa Cruz Biotechnologies Inc. CA).
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